Stock Report

Download full stock data and analysis for free Last Updated: 28-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Bliss GVS Pharma Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: BLISSGVS | BSE: 506197

₹571.00

up-down-arrow ₹10.90 (1.95%)

As on 28-Aug-2026 11:14IST

Market cap

info icon

₹6,068 Cr

Revenue (TTM)

info icon

₹1,005 Cr

P/E Ratio

info icon

44.6

P/B Ratio

info icon

4.9

Div. Yield

info icon

0.3 %

Edit peer-selector-edit
Bliss GVS Pharma Astrazeneca Pharma Caplin Point Lab CORONA Remedies Eris Lifesciences Pfizer Procter & Gamble Health Sanofi India Shilpa Medicare Strides Pharma
Market cap (₹ Cr)
 6,068 17,896 19,281 12,675 18,164 21,754 9,412 7,310 17,539 9,138
Revenue (₹ Cr)
 1,005 2,432 2,287 1,479 3,230 2,570 1,433 1,805 1,682 5,004
Net Profit (₹ Cr)
 141.74 169.62 678.07 198.55 666.92 735.15 356.88 323.80 273.51 635.34
Net Margin (%)
 13.31 6.90 28.10 13.32 20.60 26.88 24.61 17.76 16.19 12.33
RoE (%)
 11.84 20.76 19.73 30.33 18.75 19.16 58.24 43.69 11.15 19.77
Price to Earnings
 44.56 105.50 28.98 63.69 28.21 29.59 26.37 22.57 58.99 14.89
Price-To-Book
 4.92 19.79 5.12 15.71 4.49 4.94 15.29 8.85 6.53 2.79

Income Statement (₹ Cr)

Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Operating Revenue arrow
927.11 2,519.65 1,937.47 2,275.58 2,893.64
Total Income arrow
1,015.45 2,707.60 2,033.90 2,304.07 2,912.00
Total Expenditure arrow
777.88 1,615.47 1,290.54 2,013.55 1,876.44
EBITDA arrow
149.23 904.18 646.93 262.03 1,017.20
Depreciation arrow
33.48 57.73 65.96 28.58 315.46
EBIT arrow
115.75 846.45 580.97 233.45 701.74
Interest arrow
12.01 9.57 0.61 4.49 231.29
Other Income arrow
88.33 187.95 96.43 28.49 18.36
Exceptional Items arrow
-2.49 -49.16 -- -5.25 --
Profit before Tax arrow
189.59 975.67 676.78 252.20 488.87
Provision for Tax arrow
54.86 253.24 135.69 64.68 114.20
Profit after Tax arrow
134.73 722.43 541.09 187.52 374.67

Liabilities (₹ Cr)

Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Shareholder's Funds arrow
1,192.90 4,202.90 2,850.49 872.79 2,854.36
Minority Interest arrow
38.86 -- 35.90 -- 417.40
Non-Current Liabilities arrow
8.81 19.19 13.24 394.49 2,100.97
Current Liabilities arrow
235.54 627.48 305.99 1,109.50 1,489.55
Total Liabilities arrow
1,492.41 4,921.88 3,207.85 2,414.58 6,862.28

Assets (₹ Cr)

Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Non-Current Assets arrow
529.78 1,046.35 1,071.67 509.16 5,531.13
Current Assets arrow
946.34 3,803.22 2,133.95 1,859.88 1,331.15
Total Assets arrow
1,492.41 4,921.88 3,207.85 2,414.58 6,862.28
Total Debt* arrow
2.93 2.50 0.55 0.00 2,421.66
Net Current Assets arrow
710.79 3,175.74 1,827.96 750.38 -158.40
Contingent Liabilities arrow
10.71 370.49 0.64 121.23 64.29

Cashflow (₹ Cr)

Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Cash From Operating Activities arrow
138.72 967.57 432.37 -15.14 1,065.01
Cash Flow from Investing Activities arrow
-38.28 -561.67 -334.73 18.69 -79.97
Cash from Financing Activities arrow
-89.21 -798.31 -38.32 -91.97 -881.32
Net Cash Inflow / Outflow arrow
11.23 -392.41 59.32 -88.42 103.72

Ratios

Profitability Ratios

 Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
ROCE (%) arrow
17.40 23.39 26.22 31.24 13.59
ROE (%) arrow
12.11 17.16 21.72 23.02 13.81
ROA (%) arrow
9.70 14.91 18.37 8.90 5.48
EBIT Margin (%) arrow
25.62 43.34 38.37 12.77 35.79
Net Margin (%) arrow
13.27 26.68 26.60 8.14 12.87
Cash Profit Margin (%) arrow
17.37 29.72 31.33 9.47 23.22

Growth Ratios

 Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Revenue Growth (%) arrow
14.50 10.45 14.37 32.59 44.02
EBIT Growth (%) arrow
45.59 19.68 20.21 -1.38 48.22
Net Profit Growth (%) arrow
49.27 -5.88 17.27 62.02 -5.65
EPS Growth (%) arrow
52.57 -5.88 17.25 62.02 -10.39
Book Value Growth (%) arrow
13.14 -0.34 23.77 13.51 10.19

Valuation Ratios

 Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Price / Earnings arrow
17.66 29.89 28.38 103.45 54.83
Price / Book Value arrow
1.93 5.14 5.52 22.39 6.78
Dividend Yield (%) arrow
0.70 1.59 0.30 0.46 0.52
EV/EBITDA arrow
8.91 16.93 19.78 65.23 20.75
Market Cap (₹ Cr) arrow
2,280.33 21,592.90 15,219.80 19,398.64 19,292.77

Solvency Ratios

 Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Debt to Equity arrow
0.00 0.00 0.00 0.00 0.85
Short term debt to equity ratio arrow
0.00 0.00 0.00 -- 0.14
Current Ratio arrow
4.02 6.06 6.97 1.68 0.89
Quick Ratio arrow
3.38 5.31 5.88 0.75 0.67
Interest Coverage arrow
16.79 102.95 1,110.48 57.17 3.11

Operating Efficiency Ratios

 Bliss GVS Pharma Pfizer Caplin Point Lab Astrazeneca Pharma Eris Lifesciences
Debtors to sales (%) arrow
55.79 7.22 32.65 9.39 15.85
Asset Turnover arrow
0.70 0.54 0.66 1.08 0.43
Receivable days arrow
180.13 26.06 110.70 31.88 54.07
Inventory Days arrow
52.09 65.95 65.86 126.03 32.16
Payable days arrow
75.40 81.01 105.88 163.79 140.91
Cash Conversion Cycle arrow
156.82 11.00 70.68 -5.88 -54.68
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...